Gilead Sciences Valuation
| GILD Stock | USD 92.58 0.17 0.18% |
At this time, the firm appears to be fairly valued. Gilead Sciences retains a regular Real Value of $96.02 per share. The prevalent price of the firm is $92.58. Our model calculates the value of Gilead Sciences from evaluating the firm fundamentals such as Return On Asset of 0.12, return on equity of 0.0056, and Current Valuation of 133.59 B as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Gilead Sciences' valuation include:
Price Book 6.2455 | Enterprise Value 133.6 B | Enterprise Value Ebitda 34.0968 | Price Sales 4.0772 | Forward PE 12.3001 |
Fairly Valued
Today
Please note that Gilead Sciences' price fluctuation is very steady at this time. Calculation of the real value of Gilead Sciences is based on 3 months time horizon. Increasing Gilead Sciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Gilead stock is determined by what a typical buyer is willing to pay for full or partial control of Gilead Sciences. Since Gilead Sciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Gilead Stock. However, Gilead Sciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 92.58 | Real 96.02 | Target 85.47 | Hype 92.76 | Naive 93.06 |
The real value of Gilead Stock, also known as its intrinsic value, is the underlying worth of Gilead Sciences Company, which is reflected in its stock price. It is based on Gilead Sciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Gilead Sciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Gilead Sciences helps investors to forecast how Gilead stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Gilead Sciences more accurately as focusing exclusively on Gilead Sciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Gilead Sciences' intrinsic value based on its ongoing forecasts of Gilead Sciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Gilead Sciences' closest peers. If more than one evaluation category is relevant for Gilead Sciences we suggest using both methods to arrive at a better estimate.
Gilead Sciences Cash |
|
Gilead Valuation Trend
Comparing Gilead Sciences' enterprise value against its market capitalization is a good way to estimate the value of Gilead Sciences uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Gilead Revenue by Product
Gilead Sciences Total Value Analysis
Gilead Sciences is currently expected to have valuation of 133.59 B with market capitalization of 115.38 B, debt of 24.99 B, and cash on hands of 6.14 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Gilead Sciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
133.59 B | 115.38 B | 24.99 B | 6.14 B |
Gilead Sciences Investor Information
About 88.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.53. Gilead Sciences last dividend was issued on the 13th of December 2024. The entity had 2:1 split on the 28th of January 2013. Based on the key indicators related to Gilead Sciences' liquidity, profitability, solvency, and operating efficiency, Gilead Sciences may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Gilead Sciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Gilead Sciences has an asset utilization ratio of 43.65 percent. This indicates that the Company is making $0.44 for each dollar of assets. An increasing asset utilization means that Gilead Sciences is more efficient with each dollar of assets it utilizes for everyday operations.Gilead Sciences Ownership Allocation
Gilead Sciences has a total of 1.25 Billion outstanding shares. The majority of Gilead Sciences outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Gilead Sciences to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Gilead Sciences. Please pay attention to any change in the institutional holdings of Gilead Sciences as this could imply that something significant has changed or is about to change at the company. On June 14, 2024, Senator Tommy Tuberville of US Senate acquired under $15k worth of Gilead Sciences's common stock.Gilead Sciences Profitability Analysis
The company reported the previous year's revenue of 27.12 B. Net Income was 5.61 B with profit before overhead, payroll, taxes, and interest of 21.62 B.Gilead Sciences Past Distributions to stockholders
| 27th of September 2024 | ||
| 27th of June 2024 | ||
| 28th of March 2024 | ||
| 28th of December 2023 | ||
| 15th of December 2023 | ||
| 28th of September 2023 | ||
| 29th of June 2023 | ||
| 30th of March 2023 | ||
| 29th of December 2022 |
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Gilead Sciences' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Gilead Sciences and how it compares across the competition.
About Gilead Sciences Valuation
The stock valuation mechanism determines Gilead Sciences' current worth on a weekly basis. Our valuation model uses a comparative analysis of Gilead Sciences. We calculate exposure to Gilead Sciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Gilead Sciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 27.1 B | 28.5 B | |
| Pretax Profit Margin | 0.25 | 0.27 | |
| Operating Profit Margin | 0.28 | 0.29 | |
| Net Profit Margin | 0.21 | 0.22 | |
| Gross Profit Margin | 0.76 | 1.07 |
A single share of Gilead Sciences represents a small ownership stake in the entity. As a stockholder of Gilead, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
Gilead Sciences Dividends Analysis For Valuation
As of December 1, 2024, Dividends Paid is expected to decline to about 3.4 B. In addition to that, Dividend Yield is expected to decline to 0.03. At present, Gilead Sciences' Earnings Yield is projected to increase slightly based on the last few years of reporting. The current year's Price Earnings Ratio is expected to grow to 20.43, whereas Retained Earnings Total Equity is forecasted to decline to about 12.7 B.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 3.8 B | 3.4 B | |
| Dividend Yield | 0.04 | 0.03 | |
| Dividend Payout Ratio | 0.67 | 0.64 | |
| Dividend Paid And Capex Coverage Ratio | 1.82 | 1.73 |
There are various types of dividends Gilead Sciences can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of Gilead shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from Gilead Sciences directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When Gilead pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of Gilead Sciences by the value of the dividends paid out.
Gilead Sciences Growth Indicators
Investing in growth stocks can be very risky. If the company such as Gilead Sciences does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.3 B | |
| Quarterly Earnings Growth Y O Y | -0.422 | |
| Forward Price Earnings | 12.3001 |
Gilead Sciences Current Valuation Indicators
Valuation refers to the process of determining the present value of Gilead Sciences and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Gilead we look at many different elements of the entity such as Gilead's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Gilead Sciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Gilead Sciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Gilead Sciences' worth.Complementary Tools for Gilead Stock analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |